PubRank

Myron Schwartz

Author PubWeight™ 162.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 54.30
2 Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008 11.27
3 Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 9.20
4 Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013 5.05
5 Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005 4.51
6 Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009 4.50
7 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
8 Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 4.03
9 Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007 3.85
10 The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009 3.18
11 Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 2.42
12 Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011 2.39
13 A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006 2.32
14 Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004 2.29
15 Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003 2.18
16 Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2006 1.98
17 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
18 IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 1.66
19 Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol 2013 1.65
20 Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015 1.53
21 Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002 1.52
22 Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 2009 1.48
23 The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int 2010 1.48
24 Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis 2011 1.46
25 De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci 2006 1.45
26 Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl 2004 1.44
27 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012 1.44
28 Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc 2012 1.09
29 Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest 2012 1.09
30 Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol 2008 1.09
31 Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009 1.02
32 Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol 2010 1.00
33 Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist 2005 0.96
34 Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 2012 0.95
35 Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004 0.93
36 Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004 0.91
37 Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol 2013 0.91
38 Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 2011 0.91
39 Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl 2005 0.90
40 The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant 2004 0.88
41 Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis 2008 0.87
42 Resection of hepatocellular carcinoma without cirrhosis. Ann Surg 2012 0.87
43 Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003 0.87
44 Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology 2010 0.86
45 Establishing an international training program for surgical residents. J Surg Educ 2007 0.85
46 Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis 2010 0.84
47 Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes 2005 0.84
48 Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol 2012 0.83
49 Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci 2009 0.83
50 Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett 2003 0.82
51 Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011 0.82
52 Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas 2011 0.82
53 Adult-adult living donor liver transplantation. J Gastrointest Surg 2004 0.82
54 Liver transplantation for hepatocellular carcinoma. Hepatol Res 2007 0.81
55 Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis 2006 0.81
56 Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 2008 0.81
57 The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer 2014 0.81
58 Hand-assisted laparoscopic donor hepatectomy for living related transplantation in the porcine model. Surg Laparosc Endosc Percutan Tech 2002 0.80
59 Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. J Surg Oncol 2014 0.79
60 Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis 2008 0.77
61 Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB (Oxford) 2012 0.77
62 Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol 2013 0.77
63 Unresectable squamous cell carcinoma of donor origin treated with immunosuppression withdrawal and liver retransplantation. Am J Transplant 2004 0.76
64 Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas 2016 0.75
65 Outcomes in hepatitis B transplant candidates with or without hepatocellular carcinoma: UNOS policy vindicated! Liver Transpl 2007 0.75
66 Surgical treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 2010 0.75
67 Reply:. Hepatology 2013 0.75
68 Survey of health needs and concerns of rural Pennsylvanians. J Agromedicine 2005 0.75
69 The financial impact of interim and prospective payment systems on home health providers in rural communities. J Health Care Poor Underserved 2005 0.75
70 HazDat in action. Occup Health Saf 2006 0.75